These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35489378)

  • 1. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.
    Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V;
    Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
    Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
    Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
    Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand.
    Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M
    J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study.
    Ten Brink DC; Martin-Hughes R; Minnery ME; Osborne AJ; Schmidt HA; Dalal S; Green KE; Ramaurtarsing R; Wilson DP; Kelly SL
    PLoS One; 2022; 17(5):e0268240. PubMed ID: 35617169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
    Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
    J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
    Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
    Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
    Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
    Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis.
    Phillips AN; Bansi-Matharu L; Shahmanesh M; Hargreaves JR; Smith J; Revill P; Sibanda E; Ehrenkranz P; Sikwese K; Rodger A; Lundgren JD; Gilks CF; Godfrey C; Cowan F; Cambiano V
    Lancet Glob Health; 2023 Oct; 11(10):e1648-e1657. PubMed ID: 37734807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
    Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel.
    Ginsberg GM; Chemtob D
    BMC Public Health; 2020 Feb; 20(1):271. PubMed ID: 32103750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.
    Price JT; Wheeler SB; Stranix-Chibanda L; Hosek SG; Watts DH; Siberry GK; Spiegel HM; Stringer JS; Chi BH
    J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 2(Suppl 2):S145-53. PubMed ID: 27355502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect on HIV transmission and cost-effectiveness of programmes for female sex workers in East, Central, and Southern Africa: a modelling study.
    Bansi-Matharu L; Revill P; Taramusi I; Steen R; Chabata ST; Busza J; Mangenah C; Musemburi S; Machingura F; Desmond N; Matambanadzo P; Shahmanesh M; Yekeye R; Mugurungi O; Cowan FM; Hargreaves JR; Phillips AN
    Lancet Glob Health; 2024 Sep; 12(9):e1436-e1445. PubMed ID: 39151979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.
    Gomez GB; Borquez A; Caceres CF; Segura ER; Grant RM; Garnett GP; Hallett TB
    PLoS Med; 2012; 9(10):e1001323. PubMed ID: 23055836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis.
    Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M
    J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.
    Zhao R; Fairley CK; Cook AR; Phanuphak N; He S; Tieosapjaroen W; Chow EPF; Phillips TR; Jin Tan RK; Wei Y; Shen M; Zhuang G; Ong JJ; Zhang L
    Lancet Glob Health; 2024 Feb; 12(2):e243-e256. PubMed ID: 38245115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa.
    Grant H; Gomez GB; Kripke K; Barnabas RV; Watts C; Medley GF; Mukandavire Z
    Sex Transm Dis; 2020 Nov; 47(11):767-777. PubMed ID: 33044426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
    Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
    Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.